Black Diamond Therapeutics Q2 net loss narrows to $9.91 million; revenue remains no revenue
BDTX•Cash position and runway
Cash, cash equivalents and investments totaled $110.5 million at June 30, 2026, funding operations into the second half of 2028.
R&D falls while G&A rises
R&D spending dropped 20.67% to $7.39 million, reflecting lower NSCLC trial costs partly offset by GBM Phase 2 startup activity.
G&A expense rose 13.73% to $4.66 million on higher IP-related costs; interest income slipped 17.53% to $922,000.
Q2 loss narrows as expenses decline
Black Diamond Therapeutics posted a Q2 net loss of $9.91 million, narrowing from a $10.56 million loss a year earlier.
Operating loss narrowed to $12.06 million as total operating expenses fell 10.16% to $12.06 million.
